ViroLogic Announces Presentations at the 96th Annual Meeting of the American Association for Cancer Research (AACR)

ViroLogic Announces Presentations at the 96th Annual Meeting of
the American Association for Cancer Research (AACR) 


SOUTH SAN FRANCISCO, Calif., April 7  /PRNewswire-FirstCall/ -- ViroLogic, Inc.
(NASDAQ:VLGC) announced today that four presentations related to its eTag
technology will be made at the 96th Annual Meeting of the American Association
for Cancer Research (AACR), taking place April 16-20 in Anaheim, California.

    Details are as follows:

    Presentation Time:  Monday, April 18, 8:00 am - 12:00 pm
    Presentation Number:  2309
    Cellular Responses to PI3K/AKT and MAPK Pathway Inhibition in Melanoma

    Presentation Time:  Tuesday, April 19, 8:00 am - 12:00 pm
    Presentation Number:  3688
    Correlation of ErbB Activation Status and Clinical Response to Herceptin
     Treated Breast Cancer Patients

    Presentation Time:  Tuesday, April 19, 1:00 pm - 5:00 pm
    Presentation Number:  4567
    IC50 Determination for Receptor-Targeted Compounds and Downstream
     Signaling

    Presentation Time:  Wednesday, April 20, 8:00 am - 12:00 pm
    Presentation Number:  5762
    Multiplexed Assay for Assessing ErbB/HER Receptor Pathways in Formalin-
     fixed and Paraffin-embedded Cancer Cell Lines

  About the eTag System


ViroLogic's eTag assays enable detailed analysis of protein drug targets and
signaling pathways in cancer cells, including samples that are formalin-fixed,
paraffin-embedded, which is the standard format in most pathology labs. The
assays can provide information on a drug's mechanism of action, selectivity and
potency in a biological setting in pre-clinical research, and enable enrichment
or selection of clinical trial populations later in a drug's development. In
addition, ViroLogic believes these assays will be used to help physicians
better determine whether certain therapies are more appropriate for individual
cancer patients, and whether to combine therapies with different mechanisms or
properties.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious infectious diseases and cancer. The Company's products are
designed to help doctors optimize treatment regimens for their patients that
lead to better outcomes and reduced costs. The Company's technology is also
being used by numerous biopharmaceutical companies to develop new and improved
antiviral therapeutics and vaccines as well as targeted cancer therapeutics.
More information about the Company and its technology can be found on its web
site at http://www.virologic.com/. 

DATASOURCE: ViroLogic, Inc.



CONTACT:  Alfred Merriweather, Vice President and CFO of ViroLogic, Inc.,

[phone]; or Carolyn Bumgardner Wang of WeissComm Partners,

[phone], or , for ViroLogic, Inc.



Web site:  http://www.virologic.com/ 

Copyright